ACER

Acer Therapeutics Inc. Common Stock (DE)
ACER

Delisted

ACER was delisted on the 8th of November, 2023.

Back to rankings
 

About: Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

Employees: 33

Healthcare Drug Manufacturers - General

Financial journalist opinion

Neutral
PRNewsWire
11 months ago
Acer Announces Q2 2024 Operating Income at NT$1.47 Billion, Up 87.9% Quarter-on-quarter and 40.3% Year-on-year
TAIPEI , Aug. 8, 2024 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its financial results for the second quarter of 2024. Consolidated revenues reached NT$67.14 billion, up 15.2% year-on-year (YoY); operating income was NT$1.47 billion, up 87.9% quarter-on-quarter (QoQ) and 40.3% YoY, with 2.2% margin; net income[1] was NT$1.40 billion with earnings-per-share NT$0.47.
Acer Announces Q2 2024 Operating Income at NT$1.47 Billion, Up 87.9% Quarter-on-quarter and 40.3% Year-on-year
See News Rankings
Charts implemented using Lightweight Charts™